UNIVERSITY OF PRETORIA

Pfizer appoints Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025, succeeding Dr. Mikael Dolsten. Boshoff will oversee all R&D functions and maintain Oncology R&D's integrated structure with Roger Dansey, M.D. as Interim Chief Oncology Officer. Johanna Bendell, M.D. will join Pfizer from Roche in 2025 as Chief Development Officer, Oncology.

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development, effective January 1, 2025, succeeding Dr. Mikael Dolsten. Boshoff will oversee all R&D functions and remain on Pfizer’s Executive Leadership Team, reporting to Chairman and CEO Dr. Albert Bourla. Roger Dansey will serve as Interim Chief Oncology Officer, assisting in selecting a permanent replacement before retiring. Johanna Bendell will join as Chief Development Officer, Oncology in 2025.

Research group at University of Pretoria studies maize and sunflower diseases, aiming for food security. Trials in South Africa show yield loss up to 50% with late maize planting. Sunflowers adapt to heatwaves by releasing pollen earlier, ensuring pollination success. Studies on Sclerotinia head rot suggest aligning flowering with summer's hottest period can control the disease.